Effect of Epirubicin Against Glioma Initiating Cells by NAKAJIMA Atsushi et al.
Effect of Epirubicin Against Glioma Initiating
Cells
著者名 NAKAJIMA Atsushi, SAMPETREAN Oltea, KOIKE
Naoyoshi, NITTA Masayuki, KAWAMATA Takakazu,
SAYA Hideyuki, MURAGAKI Yoshihiro
journal or
publication title







TWMUJ 4: 69-76, 2020
Effect of Epirubicin Against Glioma Initiating Cells
Atsushi Nakajima,１,2 Oltea Sampetrean,２Naoyoshi Koike,３Masayuki Nitta,４
Takakazu Kawamata,４Hideyuki Saya,２ and Yoshihiro Muragaki１
１
Institute of Advanced Biomedical Engineering and Science, Tokyo Women’s Medical University, Tokyo, Japan
２
Division of Gene Regulation, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan
３
Department of Radiology, Keio University School of Medicine, Tokyo, Japan
４
Department of Neurosurgery, Tokyo Women’s Medical University, Tokyo, Japan
(Accepted September 3, 2020)
(Advance Publication by J-STAGE November 21, 2020)
Background: Glioblastoma is a highly aggressive primary malignant brain tumor. New treatments, especially ones that can
eradicate subpopulations with stem-cell-like properties, are currently being explored. In vitro, epirubicin has demonstrated
toxicity towards such populations. However, epirubicin fails to readily cross the blood-brain barrier. Furthermore, its efficacy
against stem-like tumor cells growing within the neural tissue has not been fully addressed. Polymeric micelles are an ad-
vanced system developed to enhance drug delivery into tumors.
Methods: We have investigated the effect of epirubicin micelles against murine glioma initiating cells (GICs) in vitro and ex
vivo.
Results: In vitro, epirubicin micelles inhibited the sphere growth of GICs in a dose-dependent manner. Furthermore, they
also inhibited the growth of GIC-based tumors in ex vivo cultured brain slices from the tumor-bearing mice. This effect was
inversely proportional to the tumor size at the beginning of the treatment.
Conclusions: Our results suggest that epirubicin micelles are effective against murine glioma cells with stem cell properties
and their use should be initiated at an early stage.
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Introduction
Glioblastoma (GBM) is the most aggressive primary ma-
lignant brain tumor in adults. Currently, even the best
available therapy, which includes surgical resection, te-
mozolomide administration, and adjuvant radiotherapy,
１
is not curative. In malignant tumors, one of the major
causes of a poor prognosis is the existence of cells with
stem-like properties. Such cells can arise from the malig-
nant transformation of normal tissue stem cells and act as
tumor-initiating cells. Furthermore, they can give rise to
both pluripotent and differentiated daughter cells, thereby
sustaining and propagating primary and recurrent tu-
mors.
２-５
In addition, tumor cells with stem-like properties
exhibit an inherent resistance to therapy and are thus con-
sidered the true targets for novel therapies.
５，６
In the case
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of malignant brain tumors, cells with stem-like properties
are important in all stages, including tumor initiation,
maintenance, and recurrence.
７-９
However, each of these
three populations might genetically and / or phenotypi-
cally differ
１０
and therefore warrant specific targeting
analyses.
Anthracyclines are chemotherapeutic agents that are
widely used in the treatment of solid tumors, such as
ovarian and breast cancer.
１１-１４
Recently epirubicin, an an-
thracycline, has been identified as one of the FDA-
approved drugs that displayed a strong toxic effect
against primary tumor cells isolated from surgically-
resected glioblastoma samples and maintained as stem-
cell cultures in vitro.
１５
However, previous studies have
reported that epirubicin does not readily cross the blood-
brain barrier (BBB).
１６
In recent years, several drug delivery systems have
been developed to enhance drug penetration and accumu-
lation into tumors. In brain malignancies, such systems,
sometimes further modified, are also expected to over-
come the obstacle of the BBB. This can be achieved
either by formulations which enhance transport across
the BBB, by combination with transient opening of the
BBB using chemical or physical agents, or by taking ad-
vantage of the already disrupted BBB to ensure specific
accumulation of the drugs.
Polymeric micelles exploit the phenomenon known as
enhanced permeability and retention effect (EPR). The
enhanced permeability of abnormal tumor vessels allows
the micellar delivery into tumors, while poor drainage
prevents them from being washed out.
１７-１９
Furthermore,
micelles are designed to release their contents in response
to low pH, facilitating drug release in the tumor cell ly-
sosomes.
１９-２１
Epirubicin micelles have been developed and
are currently undergoing a phase 1 clinical trial in ad-
vanced solid tumors and soft tissue sarcoma. However,
their efficacy against glioma cells with stem cell proper-
ties has not yet been evaluated.
Here, we investigated the effect of epirubicin micelles
in a murine glioblastoma model, with a focus on glioma




GICs were established from Ink4a/Arf −/− NSCs/NPCs
as previously described.
２２
The culture medium (NSM)
consisted of serum-free DMEM / F 12 ( Wako, Osaka,
Japan) supplemented with recombinant human epidermal
growth factor (EGF; PeproTech, Rocky Hill, NJ, USA),
basic fibroblast growth factor (PeproTech) each at 20 ng/
ml, 200 ng / ml heparan sulfate ( Sigma Aldrich, MS,
USA), and B27 supplement without vitamin A (Invitro-
gen, Carlsbad, CA, USA). In all experiments, GICs were
dissociated to obtain single-cell suspensions before use.
Chemicals and reagents
Epirubicin micelles (NC-6300 ) were synthesized at
NanoCarrier Co., Ltd (Kashiwa, Japan) as previously de-
scribed.
２１，２３
Epirubicin micelles were provided by Kowa
(Aichi, Japan). Epirubicin was purchased from Cosmo
Bio (Tokyo, Japan). Temozolomide was purchased from
LKT Laboratories (St. Paul, MN, USA).
Micelle preparation
Epirubicin micelles were first dissolved in ultrapure
water to allow the spontaneous formation of micelles (5
μmol of epirubicin/L). The micelles were then passed
through an ADVANTEC 0.20 μm filter (ADVANTEC,
Tokyo, Japan) and frozen at −80°C until use.
Sphere growth assay
Cells were plated in ultra-low binding 96-well plates
(Corning, Corning, NY, USA) at a density of 500 cells
per well, with or without the addition of drugs at indi-
cated concentrations. The plates were incubated at 37°C
and 5％ CO2/95％ humidified air and cultured for 7 days.
Image acquisition and analysis were performed with
Biorevo BZ9000 (Keyence, Osaka, Japan) 7 days after
plating, 6 wells for each group. Sphere images were ob-
tained at the plane of maximum size.
Cell survival assay
Cell viability was measured using the WST-8 [2-(2-
methoxy-4-nitrophenyl ) -3- ( 4-nitrophenyl ) -5- ( 2,4-
disulfophenyl)-2H tetrazolium, monosodium salt] assay.
―71―
GICs were seeded in 96-well plates at a density of 5 ×
10
3
cells per well and incubated with or without drugs at
indicated concentrations for 24-48 h. Subsequently, 10 μl
of WST-8 solution was added to each well, and the plates
were incubated for an additional 1 h at 37°C. A plate
reader (Perkin Elmer, Waltham, MA, USA) was used to
measure the absorbance of each well at 450 nm. The per-
centage of viable cells was calculated by comparison
with the control wells. In each experiment, 5 wells were
quantified for each group.
Orthotopic implantation experiments
All animal experiments were approved by the Animal
Care and Use Committee of the Keio University School
of Medicine, Tokyo, Japan (No. 11020). Intracranial im-
plantations were performed as previously described.
２２
Briefly, 6-week-old female C57BL/6J mice were anes-
thetized and placed in a stereotactic frame. GICs sus-
pended in Hank’s balanced solution were injected into
the right hemisphere at the following coordinates: 2 mm
lateral and 1 mm anterior to the bregma, 3 mm below the
surface of the brain. The injection was performed over 2
min, with an additional 2-min pause before removing the
syringe. The hole was sealed with bone wax and the
scalp was closed using an autoclip applicator.
Explant culture, drug treatment, and imaging
Brains of C57BL/6 mice implanted with GICs were
dissected and cut into 150-200 μm coronal slices using a
Leica VS 1200 vibratome (Leica, Wetzlar, Germany ) .
Brain explants were cultured on Millicell-CM culture
plate inserts (Merck Millipore, Billerica, MA, USA) in
glass-bottom dishes ( IWAKI, Shizuoka, Japan ) . The
slices were maintained in NSM as previously described.
２４
NSM with or without the indicated drugs was changed
daily. Serial images were acquired with a Fluoview
FV10i inverted confocal microscope (Olympus, Tokyo,
Japan). All images in one series were acquired the same
settings: laser excitation wavelength 473 nm, transmis-
sivity 30％ (for slices from mice n#1, n#2) and laser ex-
citation wavelength 473 nm, transmissivity 50％ ( for
slices from mice n#3, n#4). Images are presented as ac-
quired at the initial settings, without corrections for the
increase in background signal due to tissue autofluores-
cence or free epirubicin fluorescence.
２５
Composite im-
ages of 4 adjacent fields, with a Z-stack of 5 images cov-
ering a depth of 40 μm, were automatically generated and
the length and width of the tumor areas were measured
with the Fluoview Software v4.2. At the end of the ex-
periment, brain slices were fixed with 4％ paraformalde-
hyde, embedded in paraffin, and sectioned to a thickness
of 4 μm. Sections were stained with a rabbit polyclonal
antibody to Iba-1 (013-27691, FUJIFILM Wako Pure
Chemical Corporation, Osaka, Japan).
Statistical analysis
Quantitative data are presented as mean ± SD from
each experiment, representative of at least three inde-
pendent experiments. Statistical analysis was performed
by one-way analysis of variance followed by Dunnett’s
test using GraphPad Prism (GraphPad Software, La Jolla,
CA, USA). A p value < 0.05 was considered statistically
significant.
Results
To analyze the effect of epirubicin and epirubicin mi-
celles on GIC survival, proliferation, and invasion, we
used an Ink4a/Arf −/−, GFP and HrasV12 - expressing GIC
cell line with a medium proliferation- and high
infiltrative-potential. Cell survival assays indicated that
short-term treatment with 250 μM temozolomide reduced
the number of viable GICs by approximately 70％, simi-
lar to a previous report in a more proliferative, but less
invasive GIC line with the same genetic background.
２４
In
contrast, epirubicin and epirubicin micelles induced a
concentration-dependent decrease in the number of vi-
able cells at concentrations as low as 1-1,000 nM (Fig-
ure 1), with a 50％ reduction in the number of viable
cells at concentrations lower than 100 nM (Figure 1).
Next, we investigated the drugs in proliferating GICs
grown in a 3D sphere culture, continuously exposed to
the drugs for a period of one week. Both free epirubicin
and epirubicin micelles inhibited sphere growth at con-
centrations as low as 1 nM (Figure 2 ) . The effect of
epirubicin was slightly stronger than that of micelles ex-
pected to release an equivalent concentration; however,
the micelles exhibited a dose-dependent effect and re-
duced sphere size by approximately 90％ at 100 nM
(Figure 2). Temozolomide was less effective even at mi-
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Figure 1 GIC survival after treatment with temozolomide (TMZ) and epirubicin. A total of 5,000 
cells were seeded in each well in 100 μl NSM and treated with drugs at the indicated concentrations. 
Quantification data from a representative experiment are shown. NS, not significant; ***p<0.001; 
****p<0.0001.
Figure 2 Sphere growth of drug-treated GICs. A total of 500 cells were seeded in each well in 100 
μl NSM and treated with drugs at the indicated concentrations. Images were acquired on day 7. Quan-
tification of the sphere area relative to the control is shown for a representative experiment. NS, not 
significant; *p<0.05; **p<0.01; ****p<0.0001. Scale bar: 300 μm.
cromolar concentrations (Figure 2).
Finally, in order to assess the drugs on tumors in their
native microenvironment, the treatment was performed
using cultured coronal brain slices from mice injected
with the GICs. Tumors formed in syngeneic mice and
grown in slice culture exhibited cellular pleomorphism,
mitoses, and giant cells (Figure 3, lower left panel) and
were highly invasive (Figure 3, left upper and lower
panels). They also displayed an accumulation of Iba-1-
positive microglia around the tumor mass, as well as
small invasive foci (Figure 3, right upper and lower pan-
els). Epirubicin micelles (3 μM) significantly inhibited
tumor growth in tumors with initial diameters of less than
1 mm (Figure 4). In contrast, the inhibitory effect was
less pronounced in tumors which exceeded 1 mm (Fig-
ure 5). Notably, epirubicin micelles did not inhibit tumor
cell invasion and were slightly less effective than free
epirubicin, independent of tumor size (Figure 4 and Fig-
ure 5).
Discussion
Our results demonstrated that epirubicin and epirubicin
micelles inhibited the growth of the genetically engi-
neered murine GICs both in vitro and ex vivo.
The results showing the efficacy of epirubicin against
GICs in vitro contributed to existing data and demon-
strated the toxicity against cells with stem-cell-like prop-
erties.
１５
Importantly, our results further showed that the
toxic effect of epirubicin in GICs was preserved in the
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Figure 3 Histopathological analysis of GIC-based tumors in cultured brain slices. Untreated slices 
cultured in NSM were stained with hematoxylin-eosin (HE; left panels, low and high magnification) 
and antibody to microglial marker Iba-1 (right panels, low and high magnification). Scale bar: upper 
panels, 200 μm; lower panels, 100 μm.
HE Iba-1
Figure　4　The effect of epirubicin on cultured coronal brain slices. Slices were treated with the indi-
cated drug concentrations for 4 days. Representative images for tumors with an initial maximum length 
of less than 1 mm. Scale bar: 300 μm.
micellar formulation. Since delivery in the form of mi-
celles is expected to increase the intratumoral concentra-
tion and decrease systemic side-effects, these results
highlight the potential of epirubicin micelles against most
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Figure　5　The effect of epirubicin on cultured coronal brain slices. Slices were treated with the indi-
cated drug concentrations for 4 days. Representative images for tumors with an initial maximum length 
of more than 1 mm. Scale bar: 300 μm.
malignant cells contributing to glioma initiation, the
GICs.
We also observed that epirubicin micelles reduced the
growth of GIC-based tumors in brain slice explants. The
induced murine GIC model, based on the overexpression
of H-Ras
V12
in NSCs with a deletion in the Ink4/Arf locus,
exhibits pronounced cellular pleomorphism, endothelial
proliferation, pseudopalisading, and infiltration of the tu-
mor cells, resulting in pathological features closely re-
sembling those associated with glioblastoma.
２２
The GIC-
based tumors, formed by implantation of GICs into im-
munocompetent mice, are thus highly aggressive. The ef-
ficacy of epirubicin and epirubicin micelles against GIC-
based tumors warrants their further evaluation in this
model.
Notably, our results also suggested that, in GIC-based
tumors, the effect of micelles seemed to be inversely pro-
portional to the size of the tumors at the start of treat-
ment. This result needs to be validated in vivo, using ani-
mals with intracranially implanted-GICs. A careful as-
sessment of the number and permeability of blood ves-
sels, along with an analysis of the tight junctions and the
BBB in tumors of different sizes will also be needed to
find the best therapeutic window for micelle administra-
tion.
In our model, the efficacy of the epirubicin micelles
was slightly weaker than that of free epirubicin. This
finding is consistent with previous reports and has been
attributed partially to a more rapid uptake of the free drug
and a more gradual release of the compound from mi-
celles.
２６
In addition, we found a higher number of single
cells which have invaded into the normal parenchyma in
the micelle-treated slices. This could also be due primar-
ily to the time lag before the release of the drug from mi-
celles, time lag during which GICs continue to infiltrate
into the normal brain. Studies exposing the explants to a
single dose of drugs and with longer periods of observa-
tion are needed to further investigate these aspects.
Targeting infiltrative cells is also an important issue in
vivo, where the micelles are expected to act mainly
through EPR, rather than directly crossing the BBB, thus
having the strongest effect against cells within the tumor
mass. Newer formulations have cyclic Arg-Gly-Asp
(cRGD) peptides on the surface of the micelles, peptides
which allow binding to integrins overexpressed on endo-
thelial cells and/or GBM cells. Such micelles have shown
a higher intratumoral penetration in GBM spheroids and
xenograft models
２６
and might be further exploited to tar-
get tumor cells which have invaded along blood vessels.
Furthermore, the efficacy of epirubicin micelles could
also be enhanced by combination therapies. For instance,
in mouse models of colon and pancreatic cancer, epirubi-
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cin micelles are part of a promising treatment strategy
called sonodynamic therapy (SDT).
２７
SDT involves the
delivery of high-intensity, focused ultrasound, with
epirubicin micelles as the sonosensitizer agent. This
minimally invasive combination has shown better results
than the delivery of epirubicin micelles alone, indicating
a promising method of enhancing their effect.
２７，２８
Conclusion
In conclusion, our results demonstrate that epirubicin mi-
celles are effective against GICs in vitro and during the
early stages of tumor formation in cultured brain slices.
They also suggest that the use of epirubicin micelles
should be initiated as early as possible.
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